PALUMED S. A. is a young company founded in December 2000 to create and develop new antimalarial agents and antibacterial molecules. PALUMED is also developing new chelating agents for the treatment of the Alzheimer’s disease.
PALUMED has stopped the development of the antimalarial trioxaquines in 2010 (due to a limitation of financial support) and also the development of antibioquines (due to an unexpected specific toxicity).
PALUMED is now focused on the development of specific copper chelators for the treatment of Alzheimer’s disease. One of these molecules, PA1637, is able to inhibit 100% of the loss of episodic memory in a mouse model (see Ceccom et al., Plos One, 2012, vol. 7(8), e43105). Two US patents have been delivered in 2012 (n° 8,247,356 B2 and n° 8,324,196 B2) and the EU and Canada applications have been accepted in March 2014.
A collaboration Agreement has been signed on May 28th, 2013 with a private Chinese Pharmaceutical Company to develop the molecule PA1637 as drug-candidate for the treatment of Alzheimer’s disease.